A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer
Latest Information Update: 16 Dec 2021
Price :
$35 *
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Syndax Pharmaceuticals
- 14 Dec 2021 Status changed from active, no longer recruiting to completed.
- 19 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 19 Jun 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2018.